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ABSTRACT
Aim To investigate risk factors for the development of
cardiovascular disease (CVD) and estimate the risk of
cardiovascular death in rheumatoid arthritis (RA) patients
in accordance with EULAR recommendations.
Materials and methods Outpatients with RA
≤85 years of age from a Danish hospital were invited to
participate. Patients’ risk of cardiovascular death was
calculated according to the SCORE system, based on
total cholesterol/high-density lipoprotein (HDL) ratio,
smoking habits, blood pressure, age and gender. The
SCORE was adjusted based on disease duration, IgM-RF/
anti-CCP positivity and the presence of extra-articular
manifestations. Factors such as history of CVD,
hypertension or diabetes mellitus (DM), fasting glucose,
exercise habits, body mass index (BMI) and waist
circumference were explored.
Results 836 patients participated; 71.5% women;
mean (SD) age 64.3 years (12.0); 152 (19.1%) were
already diagnosed with CVD and 74 (9.0%) with DM.
Among the 644 patients without CVD or DM, 158
(24.5%) were smokers, 229 (35.8%) had a systolic
blood pressure ≥140, 397 (65.6%) total cholesterol
≥5.0 mM/L, 326 (55.4%) low-density lipoprotein
cholesterol ≥3.0 mM/L, 18 (4.0%) women and 19
(12.1%) men had a HDL-cholesterol level below 1.2/
1.0 mM/L. BMI was >25 in 409 (63.8%). Waist
circumference was above 80/94 cm in 297 (63.3%) of
female and 111 (63.8%) of male patients, respectively,
and 418 (64.9%) exercised ≤5 times a week. Among
patients without DM, 14.3% had a fasting glucose
≥6.0 mmol/L. The SCORE was ≥5 in 122 (20.2%). They
were referred to follow-up by their GP and community
advice services.
Conclusions Systematic screening revealed several risk
factors that needed medical follow-up or support to
initiate lifestyle changes.
INTRODUCTION
It is well documented that people with rheumatoid
arthritis (RA) have excess mortality compared to the
general population, partly due to an increased risk of
cardiovascular events and cardiovascular death.1–3
Although people with RA have an increased number
of the traditional risk factors for the development of
cardiovascular disease (CVD), this does not seem to
explain all excess mortality in RA compared to the
general population.4 It seems likely that the inﬂam-
matory process and disease severity also increases the
risk of CVD.4–8 The excess risk posed by having RA
may be compared to the risk from having diabetes
mellitus (DM) type II,9–11 and is inﬂuenced by other
disease-related factors and the pharmacological treat-
ment, that is, with glucocorticoids, non-steroidal anti-
inﬂammatory drugs, methotrexate, leﬂunomide and
cyclosporine.12 13 Male gender is associated with a
greater risk of CVD.14
Longer disease duration, whether the patient is
IgM-rheumatoid factor (RF) positive and/or
anti-cyclic citrullinated peptide (anti-CCP) positive
and the presence of certain extra-articular manifes-
tations seem to be linked with the increased CVD
risk due to RA.1 15 16 In 2010, 10 European
League Against Rheumatism (EULAR) recommen-
dations for cardiovascular risk management were
published.1 Cardiovascular risk assessment in all
patients with RA was recommended. Any identiﬁed
risks should be managed according to local guide-
lines, and the patient’s risk should be scored
according to the SCORE system.17 The risk
SCORE should be adapted by a multiplication
factor of 1.5 if the patient met two of the following
three criteria: disease duration of more than
10 years, RF and/or anti-CCP positivity and the
presence of certain extra-articular manifestations18
(pericarditis, pleuritis, Felty’s syndrome, polyneur-
opathy, mononeuritis, scleritis, episcleritis, glomer-
ulonephritis, severe skin vasculitis or vasculitis in
other organs). Adequate control of disease activity
is also necessary to lower the CVD risk.1
To date, only one study has been identiﬁed that
reported results from the implementation of the
EULAR recommendations for cardiovascular risk
management in patients with RA.19 This Spanish
study reported risk scores for 200 patients, but
included patients with known CVD and DM, even
though the SCORE system is not recommended in
these patients. Furthermore, the study included
rheumatic nodules in the risk assessment, whereas,
in the EULAR recommendations, rheumatic
nodules are not on the list of extra-articular mani-
festations that affect the modiﬁed SCORE.1 18
There is a need for a larger study to assess the
impact of risk factors for CVD when implementing
the EULAR recommendations.
OBJECTIVE
The objective was to investigate the spread of trad-
itional risk factors for the development of CVD
and the risk SCORE for cardiovascular death when
implementing the EULAR recommendations for
cardiovascular risk management in a Danish hos-
pital population of outpatients with RA.
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METHODS
Implementation of the EULAR recommendations
A multidisciplinary group was established at King Christian X’s
Hospital for Rheumatic Diseases in Graasten, Denmark, to
implement the EULAR recommendations1 for RA outpatients at
the hospital. The group deﬁned the aim, the content and
planned the delivery of the screening consultations. A set of
detailed clinical guidelines was developed based on the EULAR
recommendations and national guidelines.1 20–22 Screening con-
sultations were to be delivered as 30-min nursing consultations
in addition to the patient’s normal follow-up visits. The nurses
were offered 4 h of training covering CVD and risk manage-
ment, diet and CVD and opportunities in secondary care for
lifestyle change support.
Participants
All outpatients with RA 85 years of age or less connected to
King Christian X’s Hospital for Rheumatic Diseases in
Graasten, Denmark, were invited by a standard letter to a
screening consultation.
Study design
Before the screening consultation, the patients had their fasting
glucose, triglycerides, total cholesterol, high density lipoprotein
(HDL) cholesterol and low density lipoprotein (LDL) choles-
terol levels checked.
The patient’s habits regarding smoking (smoker/non-smoker),
exercise (less than ﬁve times a week/ﬁve times a week or more),
alcohol (below or above the national recommendations of a
maximum seven units per week for women and 14 for men)
were explored. The patient’s height (cm) and weight (kg) were
measured with the patient in light clothes and without shoes,
and the patient’s body mass index (BMI) was calculated as
weight (kg) by squared height (m2). Waist circumference (cm)
was measured 2 cm above the patients’ umbilicus (midway
between the lower rib margin and the iliac crest).14 Blood pres-
sure was measured while the patient was sitting in a chair and
after at least 5 min rest.22 If the patient’s blood pressure
exceeded 5 mm Hg above the nationally recommended limits, a
total of four measures (two on each arm) were performed and
the mean of the last two measures was used.22 Each patient’s
risk SCORE was calculated based on age, gender, smoking
habits, systolic blood pressure and total cholesterol/HDL ratio.17
Denmark was considered to be a high-risk area for CVD in
Europe when implementing the screening consultations. In
accordance with the EULAR recommendations and national
guidelines for the management of RA,1 23 the risk SCORE was
multiplied by 1.5 if the patient fulﬁlled the above-mentioned
criteria. To determine whether the patient had any of the spe-
ciﬁc extra-articular manifestations, the patient was asked
whether a rheumatologist at any time had said that the patient
had arthritis apart from in the joints, such as in the eyes, nerves,
the vascular system or in other organs. The ﬁndings from the
screening were discussed with the patient and advice and train-
ing in relation to identiﬁed risks were offered. Patients were
referred to follow-up by the general practitioner (GP) in cases in
which the modiﬁed risk SCORE was 5% or greater. Patients
with blood pressure above the recommended level, total choles-
terol above 8 mmol/L or fasting glucose of 6 mmol/L or greater
were also referred to their GP. Patients were informed about
opportunities to receive additional lifestyle change support in
community health centres. Written pamphlets concerning
smoking cessation, low-lipid diet and RA were offered.
The patient was offered a page with the actual risk SCORE
written on the SCORE chart and the other results from the
screening to take home. The ﬁndings from the consultations
were documented in a Danish rheumatological quality database,
the DANBIO registry, and in the patient’s journal. Following the
consultation, a copy of the note in the journal was sent electron-
ically to the patient’s GP. Patients with known DM or CVD or a
risk SCORE of 5% or greater will be invited for a follow-up
screening visit in 1 year, if they are interested; patients without
known DM or CVD and a SCORE of less than 5% will be
invited for a new screening consultation in 2 years. Patients over
the age of 80 years will only be invited again if they express a
wish for a new screening consultation.
Statistical analysis
STATA V.10.1 was used to perform descriptive statistical ana-
lyses. Results are reported with mean and SD or median and
IQR depending on the distribution of the data. Percentages are
calculated based on the number of observations available for
each variable.
RESULTS
From September 2011 to November 2012, 836 patients
accepted and completed a screening consultation (74.3% of the
hospital RA population); 598 (71.5%) were women. Reasons to
decline were due to severe disability or co-morbidities, or that it
was difﬁcult for them to attend due to transportation or work-
related issues. Some patients felt that their GP already took care
of the content in the screening consultation or that they did not
want to discuss lifestyle issues. Approximately 10% of the
patients declined to participate, but the exact number was not
recorded.
Patients’ disease activity measured by the disease activity score
in 28 joints (DAS28)–C reactive protein (CRP) score24 and
physical disability measured by the health assessment question-
naire (HAQ)25 were not recorded in the screening consultations;
however, we drew data from an outpatient visit if it was per-
formed within 2 months before or after the screening consult-
ation in order to characterise the population. For some of the
patients the most recent follow-up fell outside the 2-month
range. DAS28–CRP was thus available in only 526 patients and
the HAQ in 626 patients. The demographic and disease-related
data relating to the screened population are set out in table 1.
Among the screened patients, 349 (42.0%) were already diag-
nosed with hypertension, 152 (19.1%) with ischaemic CVD and
74 (9.0%) with DM.
The spread of the traditional risk factors for ischaemic CVD
is reported in table 2 for all 836 patients.
Out of the 748 patients without previously diagnosed DM,
95 (14.3%) had an impaired fasting glucose (≥6.0 mmol/L),
which means that DM cannot be excluded. A fasting glucose of
7.0 or greater indicates that the patient probably has undiag-
nosed DM. A total of 15 patients (2.0%) had a fasting glucose
of 7.0 or greater.
Out of the 836 screened patients, 644 patients (77%) were
not previously diagnosed with DM or CVD. The number of
patients exceeding the recommended levels for each risk factor
is shown in table 3.
Thirty-four patients reported that they had both CVD and
DM. The recommended level for LDL cholesterol is 1.8 mmol/
L or less for this group14 and 25 (73.5%) of these patients did
not meet that recommendation. Among the 349 patients with
known hypertension who already received antihypertensive
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medication, only 189 (54.2%) had a systolic blood pressure
below 140 mm Hg.
The SCORE system is not recommended for patients with
known CVD and or DM as the SCORE chart will underestimate
their risk.17 Due to a lack of blood test results in some of the
644 patients without known DM and CVD, we only managed
to obtain a risk SCORE on 605 patients. In 170 (28.1%) of
these patients the multiplication factor 1.5 was applied.
Based on the European recommendations, a SCORE less than
5% is considered to be low to moderate risk, 5–10% is high risk
and 10% or greater is very high risk for cardiovascular death
within 10 years.14 The risk SCORE are reported in table 4.
When Denmark was considered to be a high-risk country,
20.2% of the patients without previously diagnosed CVD or
DM had a high or very high risk (≥5%) for cardiovascular
death within 10 years. Due to a reduced number of cardiovascu-
lar deaths, Denmark is now considered to be a low-risk area
according to new recommendations from the European and
Danish Societies of Cardiology.14 26 The number of patients
with a SCORE of 5% or greater thus decreases to 16.2%. The
corresponding number for female patients is 11.4%, decreasing
to 6.9% and for male patients 45.3%, decreasing to 42.6%
when using the low-risk score charts.14
DISCUSSION
By implementing systematic screening for cardiovascular risk
factors in nursing consultations, the patient, the outpatient
department and the patient’s GP attained an overview of the
patient’s individual risk proﬁle. This arrangement also allowed
us to explore the patient’s motivation for lifestyle changes and
offer relevant health promotional training relating to the
patient’s everyday life, and offer written information (bro-
chures) and support to initiate desired lifestyle changes in
primary care.
Initiation or adjustment of lipid-lowering or anti-hypertensive
medication or follow-up on lifestyle issues in general would
require extra follow-up visits, and we considered that the work
involved would lie outside the rheumatologists’ core compe-
tences. We therefore chose to refer these patients to their GPs.
The screened patients seem representative of the more than
16 000 Danish RA patients registered in the DANBIO registry
(73% women and 73% RF positive).27 The patients seen at
King Christian X’s Hospital for Rheumatic Disease represent
more than 90% of known patients with RA in the uptake area
for the hospital.28
We found that 14.3% of the patients without known DM had
an impaired fasting glucose (≥6.0 mmol/L), meaning that DM
cannot be excluded.29 Two per cent had a fasting glucose of
7 mmol/L or greater, which is considered in Denmark to be the
threshold for diagnosing DM.29 The percentages with elevated
fasting glucose above 6 and 7 mM/L were even higher in the
subgroup with known CVD (27.2% and 10.3%, respectively).
In a Danish study from 2003, the prevalence of impaired fasting
glucose varied between 4.7% and 17.8%, depending on age and
gender.30 The prevalence of DM is increasing and increases
with increasing age, BMI, lack of physical activity and male
gender.30
CVD was already known in 19.1% of the patients and 42%
were diagnosed with hypertension, compared to 9.3% with
CVD and 32% with hypertension in a European sample.31
Although 42% of our sample was already treated with anti-
hypertensive drugs, only 54.2% of these patients had a systolic
blood pressure below 140 mm Hg at the time of the consult-
ation. The prevalence of a well-treated systolic blood pressure is
a little higher in the Danish general population (63.1%).32
Unfortunately, 63.8% in the group who were already known to
have CVD had elevated high blood pressure and, among
Table 1 Demographic and disease characteristics of the included
population
n=
Female gender 598 (71.5%)
Age, years (mean±SD) 64.3 (12.0) 836
Disease duration 9(5–17) 814
Positive anti-CCP 580 (90.5%) 641
Positive RF 690 (87.2%) 791
CRP (0–10) 3 (1–7) 538
DAS28–CRP (0–10) 2.4 (1.8–3.2) 526
Low (DAS28–CRP <2.6) 298 (56.7%)
Moderate (2.6≤ DAS28–CRP ≤3.2) 108 (20.5%)
High (DAS28–CRP >3.2) 120 (22.8%)
HAQ 0.5 (0.125–1.0) 626
Being treated with prednisolone (0/1) 75 (9.0%) 836
Being treated with DMARD (0/1) 660 (78.9%) 836
Being treated with anti-TNF (0/1) 168 (20.1%) 836
Known hypertension (0/1) 349 (42.0%) 831
Known ischaemic CVD (0/1) 152 (19.1%) 794
Men 53 (24%) 221
Women 99 (17.3%) 573
Known DM (0/1) 74 (9.0%) 822
Alcohol above limits (n) 50 (6.4%) 787
Women >7 units per week 19 (3.4%) 560
Men >14 units per week 31 (13.7%) 227
Anti-CCP, anti-cyclic citrullinated peptide; anti-TNF, anti-tumour necrosis factor; Being
treated with DMARD, could be one or more disease-modifying antirheumatic drug;
CRP, C-reactive protein; CVD, cardiovascular disease; DAS28–CRP, disease activity
score in 28 joints, CRP and patient global assessment score; DM, diabetes mellitus,
percentages are calculated based on number of observations for each variable; HAQ,
health assessment questionnaire; (n=), number and percentage of the population;
mean (SD), SD or median (IQR), IQR, as appropriate; RF, rheumatoid factor.
Table 2 The spread of cardiovascular risk factors for all the
patients with number and percentage of the patients with
observations or median and IQR range
Variable All patients N
Current smokers (0/1) (n) 192 (23.0%) 836
SBP (mm Hg) 135 (123–144) 830
DBP (mm Hg) 83 (76–90) 829
Total cholesterol (mM/L) 5.2 (4.6–5.9) 794
LDL-cholesterol (mM/L) 3.0 (2.4–3.7) 771
HDL-cholesterol (mM/L)
Women 1.8 (1.5–2.1) 573
Men 1.5 (1.2–1.7) 221
Triglycerides (mM/L) 1.04 (0.78–1.39) 791
Fasting glucose (mM/L) 5.4 (5–5.7) 729
BMI (kg/m2) 26.5 (23.5–30.3) 833
Waist circumference (cm) 835
Women 85 (78–96) 597
Men 99 (92–106) 238
Exercise <5 times a week (n) 552 (66.0%) 836
BMI, body mass index calculated as weight (kg)/squared height (m2); DBP, diastolic
blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; mM/L,
milli Mol per litre; SBP, systolic blood pressure.
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Table 3 The number of patients exceeding the recommended levels reported for patients with no known DM or CVD and for the subgroups of
patients with known CVD or DM displayed separately
Variable No DM or CVD Known CVD Known DM
n= n=152 n=74
Women 448 (69.6%) 644
Current smokers (0/1) 158 (24.5%) 644 26 (17.1%) 11 (14.9%)
Normal BP (SBP <140) 411 (64.2%) 640 97 (63.8%)
Diabetes patients (SBP <130) 19 (26.4%)
Light HT (SBP 140–159) 168 (26.3%) 644 38 (25.0%)
Diabetes patients (SBP 130–159) 44 (61.1%)
Moderate HT (SBP 160–179) 48 (7.5%) 644 12 (7.9%) 6 (8.3%)
Severe HT (SBP ≥180) 13 (2.0%) 644 5 (3.3%) 3 (4.2%)
Total cholesterol ≥5.0 mMol/L 397 (65.6%) 605
Diabetes or CVD (≥4.5 mM/L) 98 (64.5%) 41 (57.7%)
LDL-cholesterol ≥3.0 mMol/L 326 (55.4%) 588
Diabetes or CVD ≥1.8 mM/L) 128 (84.2%) 55 (80.9%)
HDL-cholesterol 605
Women (≤1.2 mM/L) 18 (4.0%) 448
Men (≤ 1.0 mM/L) 19 (12.1%) 157
Diabetes patients (≤ 1.0 mM/L) 4 (2.6%) 2 (2.8%)
Triglycerides >1.7 mM/L 70 (11.6%) 602
Diabetes or CVD >2.0 mM/L 17 (11.2%) 10 (14.1%)
F-glucose ≥6.0 mmol/L 71 (12.7%) 559 37 (27.2%)
F-glucose ≥7.0 mmol/L 10 (1.8%) 559 14 (10.3%) 23 (36.5%)
Overweight (BMI >25) 409 (63.8%) 641 96 (63.2%) 55 (74.3%)
Obese (BMI >30) 163 (25.4%) 641 42 (27.6%) 29 (39.2%)
High waist circumference 643
Women (>80 cm) 297 (63.3%) 469 66 (66.7%) 42 (79.2%)
Men (>94 cm) 111 (63.8%) 174 36 (67.9%) 16 (76.2%)
Exercise <5 times a week 418 (64.9%) 644 48 (31.6%) 54 (73.0%)
Percentages are calculated based on the number of observations for each variable in each subgroup.
BMI, body mass index calculated as weight (kg)/squared height (m2); CVD, cardiovascular disease; F, fasting; HDL, high-density lipoprotein; HT, hypertension; LDL, low-density
lipoprotein, SBP, systolic blood pressure in mm Hg.
Table 4 High-risk modified SCORE based on Denmark considered being a high-risk area and the extra RA risk for the 644 patients without DM




European high-risk area RA modified SCORE
Risk SCORE 2 (1, 4) 2 (1, 3) 4 (3, 7)
Low/moderate risk 483 (79.8%) 397 (88.6%) 86 (54.8%)
High risk 101(16.7%) 48 (10.7%) 53 (33.8%)
Very high risk 21 (3.5%) 3 (0.7%) 18 (11.5%)
European low-risk area SCORE
Low/moderate risk 529 (87.4%) 426 (95.1%) 103 (65.6%)
High risk 67 (11.1%) 21 (4.7%) 46 (29.3%)
Very high risk 9 (1.5%) 1 (0.2%) 8 (5.1%)
European low-risk area RA modified SCORE
Risk SCORE 2 (1, 4) 1.5 (1, 3) 4 (2, 6)
Low/moderate risk 507 (83.8%) 417 (93.1%) 90 (57.3%)
High risk 77 (12.7%) 30 (6.7%) 47 (29.9%)
Very high risk 21 (3.5%) 1 (0.2%) 20 (12.7%)
Median and (IQR). The number of patients without known DM and CVD are reported for low/moderate risk (<5%), high risk (5 ≤high risk <10%) and very high risk (≥10%) and the
percentages of the population without DM and CVD that we obtained a risk score for and stratified by gender. For gender-specific numbers, the percentages are calculated as the share
of the female or male population with no known DM and CVD when we have obtained a risk score.
CVD, cardiovascular disease; DM, diabetes mellitus; RA, rheumatoid arthritis.
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patients with DM, 73.6% had blood pressure above the recom-
mended level of 130 mm Hg.
Inﬂammation seems to affect the cholesterol level in a para-
doxical way, such as a decline in LDL-cholesterol when the
patient’s CRP level is increased.33 The median value and IQR
for the CRP and DAS28–CRP (table 1) are within the normal
range and thus the lipid paradox may not be applicable for our
population. Although quite a few were probably already on
lipid-lowering treatment, 55.4% of the patients without known
DM or CVD still had a LDL-cholesterol above 5.0 mmol/L.
The situation was even more exacerbated in the group of
patients with known CVD (84.2%) or DM (80.9%). There
seems to be a large gender difference in the percentages with
low HDL-cholesterol levels (ratio 3 : 1 for men/women),
whereas this does not seem to the case in the share with high
waist circumference; this concurs with the results from a US
study.34
In 2010, 20.9% of the general Danish population were
smokers and the proportion was 22.2% for residents in the
region of southern Denmark.35 Among the screened patients,
the number was 23%, decreasing to 17.1% if the patient had
known CVD and 14.9% in patients with DM, indicating that
smoking habits had changed in some patients after diagnosis. In
the general population in Denmark 46.7% are overweight (BMI
>25) and 13% are obese (BMI >30), and in the region of
southern Denmark the numbers are 49.3% and 14%.35 The
share of overweight is about one third higher (63.8%) in the
screened patients and the number of obese is doubled in
persons with RA with or without CVD (27.6/25.4%) compared
to the general population. For people with diabetes, the
problem is even greater (74.3% overweight and 39.2% obese),
reﬂecting the cause for the increasing number of DM type II
patients currently.14 Unfortunately, there is a positive linear asso-
ciation of BMI and all-cause mortality.14 36 The visceral adipose
tissue in abdominal fat promotes intracellular inﬂammatory
pathophysiological processes.36 Furthermore, the risk of hyper-
tension is up to ﬁve times higher in obese individuals than in
those with normal weight, and the risk of dyslipidaemia devel-
ops progressively with increasing BMI.36
A low alcohol intake may have a preventive effect on the
development of CVD, whereas heavy drinking seems to increase
the risk of CVD.37 38 Only 3.4% of the female and 13.7% of
the male patients reported alcohol intake above the nationally
recommended limits of 7/14 units per week, compared to
24.3% in the Danish general population above the age of
15 years and 20.8% in the region of southern Denmark.35 The
main reason for this difference is probably due to the high per-
centage of patients treated with disease-modifying antirheumatic
drugs, in which the number one choice is methotrexate, which
requires a need for alcohol restriction.23
When the high-risk country charts and RA-modiﬁed risk were
used, a ﬁfth (20.2%) of the patients had an elevated risk of car-
diovascular death. Using the SCORE charts for low-risk coun-
tries, this number is reduced to 16.2%. The SCORE may
underestimate the absolute risk of cardiovascular death in
10 years, because increased disease activity, genetic dispositions
to CVD, obesity and lack of exercise will further affect the
patient’s risk. The risk of cardiovascular events is probably
increased even before diagnosis.39 40 It is very important that
the patient’s disease activity is treated to target at the same time
as we are trying to reduce the patient’s risk through the impact
from the other risk factors.41 In our population, there were still
22.8% of patients with a DAS28–CRP above 3.2, indicating
room for improvement.
In young people the SCORE will be low, regardless of
smoking habits, cholesterol and blood pressure levels and thus
the chart may underestimate their risk.17 In the new European
guidelines for prevention of CVD,14 it is recommended that
young people with a low risk should be scored by a relative risk
chart. Furthermore, the SCORE chart only includes age groups
up to 65–70 years,17 and thus will probably underestimate the
risk for older patients.
One of the strengths of our study is the large number of
patients and the systematic documentation in a national registry.
Furthermore, most of the hospital population had been invited
for a cardiovascular risk assessment during the ﬁrst 15 months.
The study also had some limitations. Unfortunately, we are
not able to report the exact number of patients who declined to
participate and compare them to the group who participated to
assess potential bias. We did not verify the patients’ self-reported
version of whether they had extra-articular manifestations of
their RA and comorbidities in registry data or in the patients’
clinical journals. This may have caused an underestimation of
the modiﬁed risk scores. Also, we did not include information
on whether patients had a family history of CVD, if patients
were undergoing lipid-lowering treatment or whether they had
severe kidney disease.
The results from this study can help other hospitals plan the
resources needed for a systematic approach to screening. As we
have reported the SCORE for both high and low-risk countries,
other European countries can compare their risk SCORES to
the ones reported in this study.
Our results indicate gender differences in lipid status and
there are substantial gender differences in the distribution of the
risk SCORE. The other risk factors should be further explored
for age and gender differences. Future studies need to explore
the patients’ experiences of screening consultations and reasons
to decline participation, and whether the SCORE system pro-
vides a realistic estimation of the patients’ actual risk of cardio-
vascular death. This study provides a solid background for a
prospective follow-up study to determine whether the patients
actually visit their GP as recommended and whether changes in
risk and development of CVD occur over time.
CONCLUSIONS
Systematic screening revealed several risk factors that required
medical follow-up or support to initiate lifestyle changes in
order to reduce patients’ risk of CVD and cardiovascular death.
Cardiovascular risk management in patients with already known
DM or CVD needs to be improved. When using the charts for
high-risk countries, more than 20% of our patients have an
increased risk of cardiovascular death in 10 years. When using
the charts for low-risk countries, the number decreases to 16%.
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